Tarsus Pharmaceuticals, Inc. to Host Live Webcast for Q3 2025 Financial Results and Corporate Update

Tarsus Pharmaceuticals will webcast its Q3 2025 financial results and corporate update on November 4, 2025.

Quiver AI Summary

Tarsus Pharmaceuticals, Inc. will host a live webcast on November 4, 2025, at 1:30 p.m. PT to discuss its third quarter financial results and provide a corporate update. The webcast will be accessible online, with a recorded version available shortly after the event for about 90 days. Tarsus is focused on advancing its innovative treatments in eye care and infectious disease prevention, including their FDA-approved XDEMVY® for Demodex blepharitis, and developing other candidates in Phase 2 for conditions such as Ocular Rosacea and Lyme disease. Media and investor contacts are provided for further inquiries.

Potential Positives

Tarsus Pharmaceuticals is scheduled to report its third quarter 2025 financial results on November 4, indicating transparency and accountability with its stakeholders.
The company is advancing multiple therapies, including FDA-approved XDEMVY® and promising drugs in development such as TP-04 and TP-05, highlighting its commitment to innovation in eye care and infectious disease prevention.
The webcast allows for direct engagement with investors and stakeholders, fostering transparency and communication regarding corporate updates.

Potential Negatives

Despite the upcoming webcast to discuss financial results, there is no mention of any positive financial performance or milestones, raising concerns about the company's current financial health.
The press release highlights that multiple developments are still in Phase 2, indicating a slow progress in the pipeline and potential delays in achieving marketable products.
The focus on diseases with "high unmet need" may suggest that the company is addressing challenging medical conditions, which could imply inherent risks in product development and market acceptance.

FAQ

When is Tarsus Pharmaceuticals' Q3 2025 financial results webcast?

Tarsus Pharmaceuticals will host the webcast on November 4, 2025, at 1:30 p.m. PT / 4:30 p.m. ET.

How can I access the Tarsus Pharmaceuticals webcast?

Participants can access the live webcast through the link provided in the press release.

Will there be a recording of the Tarsus Pharmaceuticals webcast?

Yes, a recorded version of the call will be available shortly after the live event and archived for 90 days.

What is XDEMVY® and what condition does it treat?

XDEMVY® is an FDA-approved ophthalmic solution for treating Demodex blepharitis.

What are Tarsus Pharmaceuticals' ongoing clinical developments?

Tarsus is developing TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention, both in Phase 2 trials.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$TARS Insider Trading Activity

$TARS insiders have traded $TARS stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $TARS stock by insiders over the last 6 months:

WILLIAM J PHD LINK sold 27,116 shares for an estimated $1,545,612
AZIZ MOTTIWALA (Chief Commercial Officer) sold 17,500 shares for an estimated $765,800
BOBAK R. AZAMIAN (President/CEO and Board Chair) has made 0 purchases and 2 sales selling 12,000 shares for an estimated $632,220.
JEFFREY S FARROW (See Remarks) sold 13,608 shares for an estimated $550,035
ELIZABETH YEU LIN (Chief Medical Officer) sold 1,006 shares for an estimated $41,326

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$TARS Hedge Fund Activity

We have seen 125 institutional investors add shares of $TARS stock to their portfolio, and 81 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,324,214 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $53,643,909
JANUS HENDERSON GROUP PLC added 1,293,987 shares (+252.3%) to their portfolio in Q2 2025, for an estimated $52,419,413
TORONTO DOMINION BANK removed 872,783 shares (-46.6%) from their portfolio in Q2 2025, for an estimated $35,356,439
CITADEL ADVISORS LLC removed 763,396 shares (-76.9%) from their portfolio in Q2 2025, for an estimated $30,925,171
BLACKROCK, INC. added 638,457 shares (+20.2%) to their portfolio in Q2 2025, for an estimated $25,863,893
NORGES BANK added 471,354 shares (+inf%) to their portfolio in Q2 2025, for an estimated $19,094,550
ORBIMED ADVISORS LLC removed 455,843 shares (-69.7%) from their portfolio in Q2 2025, for an estimated $18,466,199

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$TARS Analyst Ratings

Wall Street analysts have issued reports on $TARS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 05/27/2025
Guggenheim issued a "Buy" rating on 05/02/2025

To track analyst ratings and price targets for $TARS, check out Quiver Quantitative's $TARS forecast page.

$TARS Price Targets

Multiple analysts have issued price targets for $TARS recently. We have seen 3 analysts offer price targets for $TARS in the last 6 months, with a median target of $84.0.

Here are some recent targets:

Matthew Caufield from HC Wainwright & Co. set a target price of $88.0 on 10/20/2025
Andrea Tan from Goldman Sachs set a target price of $51.0 on 05/05/2025
Eddie Hickman from Guggenheim set a target price of $84.0 on 05/02/2025

Full Release

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update.

Participants may access the webcast here . A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY ^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:

Adrienne Kemp

Sr. Director, Corporate Communications

(949) 922-0801

[email protected]

Investor Contact:

David Nakasone

Head of Investor Relations

(949) 620-3223

[email protected]